Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"RevOpsis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Neovascular AMD Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"},{"orgOrder":0,"company":"RevOpsis Therapeutics","sponsor":"Kemwell Biopharma Private Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RevOpsis and Kemwell Form Strategic Manufacturing Partnership for Biologics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by RevOpsis Therapeutics

    Menu

    RevOpsis Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              RevOpsis Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RevOpsis and Kemwell Form Strategic Manufacturing Partnership for Biologics

              Details:

              Through the partnership, RevOpsis is well-positioned to advance the clinical development of RO-104, a first-in-class lead candidate for the treatment of neovascular age-related macular degeneration.

              Lead Product(s): RO-104

              Therapeutic Area: Ophthalmology Product Name: RO-104

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: Kemwell Biopharma Private Limited

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership June 17, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              RevOpsis Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Neovascular AMD Treatment

              Details:

              Through the funding, RevOpsis is well positioned to advance clinical development of RO-104, first-in-class lead candidate for the treatment of treatment of neovascular age-related macular degeneration.

              Lead Product(s): RO-104

              Therapeutic Area: Ophthalmology Product Name: RO-104

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $16.5 million Upfront Cash: Undisclosed

              Deal Type: Funding April 25, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY